期刊文献+

寻常型银屑病患者血清MMP-2、IL-18和IL-2的检测及临床意义 被引量:3

Serum concentration of MMP-2,MMP-9,and IL-18 in the patients with Psoriasis Vulgaris and its clinical significance
下载PDF
导出
摘要 目的探讨MMP-2、MMP-9和IL-18在寻常型银屑病发生发展过程中的作用。方法以寻常型银屑病患者共73例(包括进行期48例、静止期25例)和健康对照58例样本为试验材料,采用双抗体夹心酶联免疫技术测定血清中MMP-2、MMP-9和IL-18浓度。结果进行期患者血清MMP-2、MMP-9和IL-18浓度均最高,分别为411.57±123.48ng/mL、681.42±297.31ng/mL和421.73±41.30ng/mL,显著高于静止期组和对照组(P<0.05)。治疗后血清中MMP-2、MMP-9和IL-18浓度分别为273.54±91.85ng/mL、431.65±120.81ng/mL和287.34±19.41ng/mL,均显著低于治疗前水平(P<0.05)。结论 MMP-2、MMP-9和IL-18因子在银屑病的发生、发展过程中起着重要作用,观察其浓度变化对探讨其发病机理,预防和指导用药均有重要的临床价值。 Objective We evaluated the biological roles of MMP-2,MMP-9,and IL-18 during the process of Psoriasis Vulgaris.Methods The ELISA method was adopted to detect the serum level of MMP-2,MMP-9,and IL-18 in 73 cases of Psoriasis Vulgaris,including 48 cases in developing psoriasis and 25 remission psoriasis,together with 58 normal persons in control group.Results The highest serum levels of MMP-2,MMP-9,and IL-18 were observed in developing psoriasis cases with 411.57±123.48 ng/mL,681.42±297.31 ng/mL,and 421.73 ± 41.30 ng/mL,respectively,which were significantly higher than that in remission psoriasis and control group.The serum levels of MMP-2,MMP-9,and IL-18 after treatment were 273.54 ± 91.85 ng/mL,431.65 ± 120.81 ng/mL,and 287.34 ± 19.41 ng/mL,which were significantly lower than that before treatment.Conclusion The serum levels of MMP-2,MMP-9,and IL-18 were revealed the significant difference between groups,which would suggest the important biological roles underlying the occurrence and development of Psoriasis Vulgaris disease.
出处 《中国实验诊断学》 2012年第7期1183-1185,共3页 Chinese Journal of Laboratory Diagnosis
关键词 寻常型银屑病 MMP-2 MMP-9 IL-18 血清浓度 Psoriasis Vulgaris Diseases MMP-2 MMP-9 IL-18 Serum Level
  • 相关文献

参考文献5

二级参考文献32

共引文献362

同被引文献47

  • 1郁博,陈德宇,何威.与银屑病发病相关的某些细胞因子[J].中国麻风皮肤病杂志,2007,23(8):696-698. 被引量:4
  • 2张学军.皮肤性病学[M].6版.北京:人民卫生出版社.2005:164.
  • 3Bailly-Bechet M, Borgs C, Braunstein A, et al. Finding undetected protein associations in cell signaling by belief propagation[ J]. Proc Natl Acad Sci U S A,2011, 108 (2): 882 -887.
  • 4Mewes HW, Amid C, Arnold R, et al. MIPS: analysis and annotation of proteins from whole genomes [ J]. Nucleic Acids Res,2004, 32(Database issue) : D41-44.
  • 5Zhao SW, Li S. Network-based relating pharmacological and genomic spaces for drug target identification [ J ]. Plos One, 2010, 5 (7) : e11764.
  • 6Henderson-Maclennan NK, Papp JC, Talbot CC Jr, McCabe ER, Presson AP. Pathway analysis software: annotation errors and solutions[J]. Mol Genet MeTab, 2010, 101 (2-3) : 134- 140.
  • 7Goronzy JJ, Weyand CM. T-cell regulation in rheumatoid arthritis [J]. Curr Opin Rheumatol,2004 , 16(3) : 212-217.
  • 8Oren M. Regulation of the p53 tumor suppressor protein [ J]. J Biol Chem,1999, 274(51 ) : 36031-36034.
  • 9Soini Y, Kamel D, Paakko P, Lehto VP, Oikarinen A, Vahakangas KV. Aberrant accumulation of p53 associates with Ki67 and mitotic count in benign skin lesions [ J ]. Br J Dermatol, 1994, 131 (4) : 514-520.
  • 10Huber M, Rettler I, Bernasconi K, Frenk E, Lavrijsen SP, Ponec M, Bon A, Lautenschlager S, Schorderet DF, Hohl D [ J ]. Mutations of keratinocyte transglutaminase in lamellar ichthyosis Science, 1995, 267 ( 5197 ) : 525-528.

引证文献3

二级引证文献36

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部